Αποτελέσματα Αναζήτησης
DESCRIPTION. ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE).
20 Μαΐ 2024 · What are the ingredients in ORTHO EVRA? Active ingredient: norelgestromin and ethinyl estradiol. Inactive ingredient: polyethylene, polyester, polyisobutylene/polybutene adhesive, crospovidone, non-woven polyester fabric, lauryl lactate, polyethylene terephthalate (PET) film, and polydimethylsiloxane coating.
SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
A combination of fexofenadine HCl and pseudoephedrine HCl in an extended-re-lease tablet (60 mg/120 mg) is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and chil-dren 12 years and older. For more infor-mation, contact Barr Pharmaceuticals Inc. by calling 800-222-0190 or 201-930-3302.
Overview. This is a summary of the European public assessment report (EPAR) for Evra. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Evra.
15 Ιαν 2024 · Ortho Evra skin patches (ethinyl estradiol and norelgestromin) are used as a contraceptive to prevent pregnancy. Includies Ortho Evra side effects, interactions and indications.
16 Μαΐ 2010 · Background. Norelgestromin is a drug used in contraception. Norelgestromin is the active progestin responsible for the progestational activity that occurs in women after application of ORTHO EVRA patch. Type. Small Molecule. Groups. Approved, Investigational. Structure. 3D. Download. Similar Structures. Weight. Average: 327.468.
